Schizophrenia Research Program

The Schizophrenia Research Program (SRP) is a division within the Department of Psychiatry dedicated to generating new knowledge in the neurobiology and psychopharmacology of schizophrenia and related psychoses. Its mission is to conduct clinical and translational research to advance the understanding of the causes and treatments of schizophrenia.

SRP research activities include federally funded research projects as well as industry-sponsored clinical trials and investigator-initiated studies.

The major research areas of interest include: brain structure and function, neurochemistry, postmortem histopathology, apoptosis and neurotoxicity, non-dopaminergic antipsychotic agents and metabolic complications.

The SRP collaborates with basic and clinical researchers locally and at other institutions on projects of mutual interest. It also recruits medical students and residents to participate in research and to develop research interest in schizophrenia.

For more information, please contact Karen Tugrul, BSN, RN, at 513-558-6831 or tugrulkc@ucmail.uc.edu.

Current Research Opportunities

Study for Individuals with Schizophrenia

What

KarXT is a new medication being investigated as a potential treatment for schizophrenia. This outpatient study will look at the safety of KarXT, and how well it works in improving symptoms of schizophrenia when added to existing medication. KarXT is investigational because it has not been approved by the U.S. Food and Drug Administration (FDA).

Who

• Men and women 18-59 years old, diagnosed
• with schizophrenia, currently receiving outpatient
• treatment, and still experiencing symptoms.

Pay

• Participants will receive payments for time and travel
• up to $1,800. All study visits, test procedures and study
• medications will be provided at no cost to participants.

Details

For more information contact: Karen Tugrul, BSN, RN, at 513-558-6831 or tugrulkc@ucmail.uc.edu
For additional studies: Current Studies